Steps Forward: Immunoassays for cryptic HDGFL2 flag TDP-43 proteinopathy in diverse disorders. Companies have moved a PET ligand into Phase 1 trials.

A documentary of country legend Glen Campbell's life and “Goodbye Tour” following his diagnosis of Alzheimer's.

Tau hyperphosphorylation and conformational changes in the brain parenchyma start around seven months. Tangle-like pathology is mainly observed in the brain stem and spinal cord, and to a lesser ...

Sensory Stimulation Systems, and GENUS, refer to a noninvasive procedure, i.e., a "digital therapeutic," being developed by Cognito Therapeutics. The company developed a wearable GammaSense ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Biogen’s hopes for a quick regulatory approval of its anti-Aβ antibody aducanumab may be dimming. An advisory panel convened by the U.S. Food and Drug Administration was unimpressed by the evidence ...

Studies aim to validate Alzheimer's disease blood tests against gold standard biomarkers in primary care. Scientists ask how best to incorporate AD blood tests into existing healthcare systems. Some ...

Series - Clinical Trials on Alzheimer's Disease 2018: Part 1 of 10: Bump in the Road or Disaster? BACE Inhibitors Worsen Cognition Part 2 of 10: Second Look at BAN2401 Data Still Positive, Despite ...

Series - AAT-AD/PD™ 2020 Conference: Advances in Alzheimer's and Parkinson's Therapies: Part 1 of 12: New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better Part 2 of 12: 217—The Best Phospho-Tau ...

Amyloid PET scans led to a small drop in hospitalizations, but missed the prespecified endpoint. Researchers are still analyzing the data and running add-on studies in this huge cohort. IDEAS 2 will ...

Could a dietary supplement marketed directly to consumers moonlight as an effective treatment for ALS? It is within the realm of possibility, according to the results of a small Phase 1 pilot study ...